PDF(Pubmed)
Abstract：
UNASSIGNED: Ventilator-Associated Pneumonia (VAP) is one of the most common nosocomial infections in the Pediatric Intensive Care Unit (PICU). Using new strategies to prevent nosocomial infections is crucial to avoid antibiotic resistance. One of these strategies is the utilization of probiotics. This study aims to investigate the efficacy of probiotic prophylaxis in preventing VAP in mechanically ventilated children.
UNASSIGNED: This study was a randomized, double-blind clinical trial. The study included 72 children under 12 years of age under mechanical ventilation for more than 48 h in the Mofid Children\'s Hospital. Patients were randomly divided into Limosilactobacillus reuteri DSM 17938 probiotic recipients (n = 38) and placebo groups (n = 34). In addition to the standard treatment, both groups received a sachet containing probiotics or a placebo twice a day. Children were screened for VAP based on clinical and laboratory evidence.
UNASSIGNED: The mean age of children in the intervention and placebo groups was 4.60 ± 4.84 and 3.38 ± 3.49 years, respectively. After adjusting the other variables, it was observed that chance of VAP among probiotics compared to the placebo group was significantly decreased (OR adjusted = 0.29; 95% CI: 0.09-0.95). Also, probiotic was associated with a significantly lower chance of diarrhea than the placebo group (OR adjusted = 0.09; 95% CI: 0.01-0.96).
UNASSIGNED: Probiotic utilization is effective in preventing the incidence of VAP and diarrhea in children under mechanical ventilation in the PICU.
UNASSIGNED: This study was a randomized, double-blind clinical trial. The study included 72 children under 12 years of age under mechanical ventilation for more than 48 h in the Mofid Children\'s Hospital. Patients were randomly divided into Limosilactobacillus reuteri DSM 17938 probiotic recipients (n = 38) and placebo groups (n = 34). In addition to the standard treatment, both groups received a sachet containing probiotics or a placebo twice a day. Children were screened for VAP based on clinical and laboratory evidence.
UNASSIGNED: The mean age of children in the intervention and placebo groups was 4.60 ± 4.84 and 3.38 ± 3.49 years, respectively. After adjusting the other variables, it was observed that chance of VAP among probiotics compared to the placebo group was significantly decreased (OR adjusted = 0.29; 95% CI: 0.09-0.95). Also, probiotic was associated with a significantly lower chance of diarrhea than the placebo group (OR adjusted = 0.09; 95% CI: 0.01-0.96).
UNASSIGNED: Probiotic utilization is effective in preventing the incidence of VAP and diarrhea in children under mechanical ventilation in the PICU.
摘要：
未经证实：呼吸机相关性肺炎（VAP）是儿科重症监护病房（PICU）中最常见的医院感染之一。使用新的策略来预防医院感染对于避免抗生素耐药性至关重要。这些策略之一是利用益生菌。本研究旨在探讨益生菌预防机械通气儿童VAP的疗效。
未经评估：这项研究是一项随机研究，双盲临床试验。该研究包括72名12岁以下的儿童在Mofid儿童医院接受机械通气超过48小时。患者被随机分为罗伊氏LimosilactobacillusDSM17938益生菌接受者（n=38）和安慰剂组（n=34）。除了标准治疗，两组均接受含益生菌的小袋或安慰剂,每天两次.根据临床和实验室证据对儿童进行VAP筛查。
未经评估：干预组和安慰剂组儿童的平均年龄分别为4.60±4.84和3.38±3.49岁，分别。调整其他变量后，观察到,与安慰剂组相比,益生菌组发生VAP的几率显著降低(OR校正=0.29;95%CI:0.09~0.95).此外，与安慰剂组相比,益生菌组出现腹泻的几率显著降低(OR校正=0.09;95%CI:0.01~0.96).
UNASSIGNED：益生菌的使用可有效预防PICU机械通气儿童的VAP和腹泻的发生。
未经评估：这项研究是一项随机研究，双盲临床试验。该研究包括72名12岁以下的儿童在Mofid儿童医院接受机械通气超过48小时。患者被随机分为罗伊氏LimosilactobacillusDSM17938益生菌接受者（n=38）和安慰剂组（n=34）。除了标准治疗，两组均接受含益生菌的小袋或安慰剂,每天两次.根据临床和实验室证据对儿童进行VAP筛查。
未经评估：干预组和安慰剂组儿童的平均年龄分别为4.60±4.84和3.38±3.49岁，分别。调整其他变量后，观察到,与安慰剂组相比,益生菌组发生VAP的几率显著降低(OR校正=0.29;95%CI:0.09~0.95).此外，与安慰剂组相比,益生菌组出现腹泻的几率显著降低(OR校正=0.09;95%CI:0.01~0.96).
UNASSIGNED：益生菌的使用可有效预防PICU机械通气儿童的VAP和腹泻的发生。
